Potenial Outcomes all PositiveSituation
MNCA clinical trial data show substantial survivorship increases
But, clinical patient sizes are rather small
This leads to FDA request for TTT to conduct another trial which would raise sample sizes and remove sampling uncertainty.
Outcome 1
FDA concedes and MCNA will be approved for commercial sale.
This is the very best scenario. TST will soar.
Outcome 2
FDA requires supportable data which would assuage its uncertainties yet meet its efficacy and safety concerns.
This is an intermediate scenario requiring a short term delay in commecialzation.
The share price responds in a very affirmative manner
Outcome 3
FDA does not alter its stance and another clinical trial must be done.
TST will revert to its strategic fallback position in which MCNA is out licensed to another pharma to complete the final clinical trial and TST receives a 15 % royalty on net sales.
TST then monetizes its substantial cash position and tax loss pools to acquire a suite a commecial drugs.
This is the outcome that I believe will be the most probable.
It will also be very positive, as TST continues to benefit from the commecialztion of MCNA in a costless manner and it also becomes a cash flow generator through its acquisition strategy...
With 16 cents in cash and no debt, I see only upside from here..